Doxorubicin induces cell death in breast cancer cells regardless of Survivin and XIAP expression levels

详细信息    查看全文

• 作者：Gabriela Nestal de Moraes ; Flavia C. Vasconcelos ; Deborah Delbue ; Giuliana P. Mognol ; Cinthya Sternberg ; Jo茫o P.B. Viola ; Raquel C. Maia
• 关键词：XIAP ; Survivin ; Doxorubicin ; Chemoresistance ; Breast cancer
• 刊名：European Journal of Cell Biology
• 出版年：August-September, 2013
• 年：2013
• 卷：92
• 期：8-9
• 页码：247-256
• 全文大小：2452 K

文摘

Breast cancer is the leading cause of deaths in women around the world. Resistance to therapy is the main cause of treatment failure and still little is known about predictive biomarkers for response to systemic therapy. Increasing evidence show that Survivin and XIAP overexpression is closely associated with chemoresistance and poor prognosis in breast cancer. However, their impact on resistance to doxorubicin (dox), a chemotherapeutic agent widely used to treat breast cancer, is poorly understood. Here, we demonstrated that dox inhibited cell viability and induced DNA fragmentation and activation of caspases-3, -7 and -9 in the breast cancer-derived cell lines MCF7 and MDA-MB-231, regardless of different p53 status. Dox exposure resulted in reduction of Survivin and XIAP mRNA and protein levels. However, when we transfected cells with a Survivin-encoding plasmid, we did not observe a cell death-resistant phenotype. XIAP and Survivin silencing, either alone or in combination, had no effect on breast cancer cells sensitivity towards dox. Altogether, we demonstrated that breast cancer cells are sensitive to the chemotherapeutic agent dox irrespective of Survivin and XIAP expression levels. Also, our findings suggest that dox-mediated modulation of Survivin and XIAP might sensitize cells to taxanes when used in a sequential regimen.